---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-012337"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:53:36.048371+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CervoMed appoints EVP Clinical Development and EVP Regulatory; COO Cobuzzi to depart July 1, 2025

## Summary
- Kelly Blackburn promoted to EVP Clinical Development (previously SVP), effective April 16, 2025; base salary $448,360, target bonus 35%.
- Mark De Rosch appointed EVP Regulatory and Government Affairs and Program Management, effective May 1, 2025; base salary $465,000, target bonus 35%.
- Robert Cobuzzi, COO, to depart July 1, 2025; not standing for re-election; receives lump-sum $479,723 plus pro-rated bonus and COBRA.
- Agreements include severance, non-compete, non-solicitation, and change-of-control provisions.

## SEC filing metadata
- accession: 0001437749-25-012337
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/0001437749-25-012337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/crvo20250417_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-012337
- JSON: https://secwatch.observer/filing/0001437749-25-012337.json
- Plain text: https://secwatch.observer/filing/0001437749-25-012337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.